Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne.

ABSTRACT:

Background

Trifarotene, a fourth-generation topical retinoid, offers a novel therapeutic option for facial and truncal acne. However, its role was only briefly addressed in Malaysia's 2022 Clinical Practice Guidelines (CPGs) due to its unavailability at the time. This paper aims to provide expert advisory statements on the integration of trifarotene into acne management in Malaysia, addressing evidence gaps in guideline coverage, particularly for truncal acne and acne-induced sequelae.

Methods

A literature review was conducted to synthesize evidence on trifarotene's efficacy, safety, and clinical positioning. An advisory panel of 10 Malaysian dermatologists reviewed the evidence and provided consensus through structured surveys and discussion meetings. Three illustrative cas

SUBMITTER: Mohd Affandi A 

PROVIDER: S-EPMC12745670 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature